Reduced high-molecular-weight adiponectin and elevated high-sensitivity C-reactive protein are synergistic risk factors for metabolic syndrome in a large-scale middle-aged to elderly population: The Shimanami health promoting program study

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 3, 2008, Pages 715-722

  Tabara, Yasuharu ^a   Osawa, Haruhiko ^a   Kawamoto, Ryuichi ^b   Tachibana Iimori, Rieko ^a   Yamamoto, Miyuki ^a   Nakura, Jun ^a   Miki, Tetsuro ^a   Makino, Hideich ^a   Kohara, Katsuhiko ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Seiyo Municipal Nomura Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ELDERLY CARE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEDICAL RECORD; METABOLIC SYNDROME X; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE;

EID: 40849094268     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0397     Document Type: Article

References (44)

1. National Cholesterol Education Program 2002 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
2. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G 2005 The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28:385-390
3. Koren-Morag N, Goldbourt U, Tanne D 2005 Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 36:1366-1371
4. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT 2002 The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716
5. Berg AH, Scherer PE 2005 Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96:939-949
6. Berg AH, Lin Y, Lisanti MP, Scherer PE 2004 Adipocyte differentiation induces dynamic changes in NF-κB expression and activity. Am J Physiol Endocrinol Metab 287:E1178-E1188
7. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y 1999 Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476
8. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y 2001 Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063
9. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA 2001 Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935
10. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T 2004 Adiponectin as a biomarker of the metabolic syndrome. Circ J 68:975-981
11. Tanko LB, Bruun JM, Alexandersen P, Bagger YZ, Richelsen B, Christiansen C, Larsen PJ 2004 Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: implications for atherogenesis. Circulation 110:2246-2252
12. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE 2003 Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085
13. Fisher FF, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE, Kumar S 2005 Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 48:1084-1087
14. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE 2004 Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162
15. Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO, Mohlig M, Pfeiffer AF, Spranger J 2005 Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712-2719
16. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, Matsuzawa Y 2004 Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-e31
17. Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, Tanioka T, Negoro T, Tomita M, Tobe T 2006 A novel enzyme-linked immunosorbent assay specific for high-molecular weight adiponectin. J Lipid Res 47:1572-1582
18. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y 2006 Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55:1954-1960
19. Kampus P, Kals J, Ristimae T, Fischer K, Zilmer M, Teesalu R 2004 High-sensitivity C-reactive protein affects central haemodynamics and augmentation index in apparently healthy persons. J Hypertens 22:1133-1139
20. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, Sugiura K, Kondo T, Murohara T, Toyoshima H 2006 Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26:871-876
21. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH 1998 Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-733
22. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y 2003 Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671-674
23. Kohara K, Tabara Y, Tachibana R, Nakura J, Miki T 2004 Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study. Hypertens Res 27:471-477
24. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute 2004 Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438
25. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity 2002 New criteria for 'obesity disease' in Japan. Circ J 66:987-992
26. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N 1998 Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35:745-753
27. Rifai N, Tracy RP, Ridker PM 1999 Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 45:2136-2141
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
29. Ohnishi H, Saitoh S, Takagi S, Ohata J, Takeuchi H, Isobe T, Katoh N, Chiba Y, Fujiwara T, Akasaka H, Shimamoto K 2005 Incidence of insulin resistance in obese subjects in a rural Japanese population: the Tanno and Sobetsu study. Diabetes Obes Metab 7:83-87
30. Ohnishi H, Saitoh S, Ura N, Takagi S, Obara F, Akasaka H, Oimatsu H, Shimamoto K 2002 Relationship between insulin resistance and accumulation of coronary risk factors. Diabetes Obes Metab 4:388-393
31. Fukushima M, Suzuki H, Seino Y 2004 Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 66:S37-S43
32. Wakugawa Y, Kiyohara Y, Tanizaki Y, Kubo M, Ninomiya T, Hata J, Doi Y, Okubo K, Oishi Y, Shikata K, Yonemoto K, Maebuchi D, Ibayashi S, Iida M 2006 C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke 37:27-32
33. Aono Y, Ohkubo T, Kikuya M, Hara A, Kondo T, Obara T, Metoki H, Inoue R, Asayama K, Shintani Y, Hashimoto J, Totsune K, Hoshi H, Satoh H, Izumi S, Imai Y 2007 Plasma fibrinogen, ambulatory blood pressure, and silent cerebrovascular lesions: the Ohasama study. Arterioscler Thromb Vasc Biol 27:963-968
34. Tamaki S, Nakamura Y, Tsujita Y, Nozaki A, Amamoto K, Kadowaki T, Kita Y, Okamura T, Iwai N, Kinoshita M, Ueshima H 2002 Polymorphism of the angiotensin converting enzyme gene and blood pressure in a Japanese general population (the Shigaraki Study). Hypertens Res 25:843-848
35. Taniguchi A, Fukushima M, Sakai M, Miwa K, Makita T, Nagata I, Nagasaka S, Doi K, Okumura T, Fukuda A, Kishimoto H, Fukuda T, Nakaishi S, Tokuyama K, Nakai Y 2000 Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care 23:1766-1769
36. Sekikawa A, Eguchi H, Tominaga M, Igarashi K, Abe T, Manaka H, Sasaki H, Fukuyama H, Kato T, Kiyohara Y, Fujishima M 2000 Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in a rural area of Japan. The Funagata diabetes study. J Diabetes Complications 14:78-83
37. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G 2003 Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52:1779-1785
38. Tong Q, Sankale JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK, Hotamisligil GS 2003 Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 88:1559-1564
39. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B 2004 Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219:9-15
40. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, Chen B, Lam MC, Tse C, Cooper GJ, Lam KS 2005 Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073-18080
41. Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N, Shimamoto K 2005 Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 153:91-98
42. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y 2002 Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141
43. Koshimura J, Fujita H, Narita T, Shimotomai T, Hosoba M, Yoshioka N, Kakei M, Fujishima H, Ito S 2004 Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 316:165-169
44. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I 2004 Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33